Filing Flows › Tango Therapeutics (TNGX) › Recalls, complaints & regulation
Tango Therapeutics (TNGX): clinical trials
Tango Therapeutics (TNGX) beyond its filings: 5 active clinical trials.
Tango Therapeutics' latest quarter
Tango Therapeutics, Q3 2025: revenue $53.8M (+364% year over year), operating margin 26.2%, net earnings $15.9M, operating cash flow −$31.0M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Tango Therapeutics have?
5 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.